New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA…
Munich (ots/PRNewswire) - - Newly presented data provide reassurance around edoxaban use in vulnerable populations of frail, elderly and renally impaired patients
- Clinician's perception of frailty found to potentially be a better marker of clinical outcomes than age
- The global ETNA-AF programme, which includes ETNA-AF-Europe, is the largest prospective, non-interventional study investigating a single NOAC to date
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced one-year results of four!-->…